Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy

Aim Implementing genetic analyses have unraveled rare alterations causing early-onset obesity and complications, in whom treatment is challenging. We aimed to report on the effects of adjuvant off-label therapy with liraglutide, glucagon-like peptide-1 analogue (GLP-1a), in rare genetic diagnoses. M...

Full description

Saved in:
Bibliographic Details
Published inActa diabetologica Vol. 60; no. 8; pp. 1099 - 1108
Main Authors Zaitoon, Hussein, Lubetzky, Ronit, Amir, Achiya Z., Moran-Lev, Hadar, Sagi, Liora, Yacobi-Bach, Michal, Borger, Ophir, Chorna, Efrat, Lebenthal, Yael, Brener, Avivit
Format Journal Article
LanguageEnglish
Published Milan Springer Milan 01.08.2023
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aim Implementing genetic analyses have unraveled rare alterations causing early-onset obesity and complications, in whom treatment is challenging. We aimed to report on the effects of adjuvant off-label therapy with liraglutide, glucagon-like peptide-1 analogue (GLP-1a), in rare genetic diagnoses. Methods Case scenarios and review of the literature. Results Case 1: Nine-year-old boy with early-onset severe obesity and nonalcoholic fatty liver disease (NAFLD) due to a homozygous mutation in the MC4R gene deteriorated under lifestyle change and metformin therapy [at 10.5 years: body mass index (BMI) 51.2kg/m 2 , 226% of the 95th percentile, fat percentage (FP) 65% and muscle-to-fat ratio (MFR) z-score of −2.41]. One year of liraglutide treatment halted progressive weight gain [BMI 50.3kg/m 2 , 212% of the 95th percentile, 63.7% FP and MFR z-score of −2.34], with biochemical improvement. Case 2: Twelve-year-old boy with obesity presented with diabetes and progressive NAFLD. Exome analysis revealed two heterozygous mutations compatible with monogenic diabetes ( HNF1A ) and familial hypercholesterolemia ( LDLR ). Lifestyle modifications resulted in clinical and laboratory improvement (BMI 87th percentile, 32.8% FP, MFR z-score of −1.63, HbA1c 5.5%) without the expected recovery in liver transaminases. Liraglutide treatment augmented the improvement in weight status (BMI 68th percentile, 22.6% FP, MFR z-score of −1.13) with normalization of liver transaminases. Case 3: Nineteen-year-old male with spinal muscular atrophy type 3 presented with sarcopenic obesity and comorbidities. Treatment strategy included dietary counseling and multiple drug therapies (metformin, anti-hypertensive and statins). Liraglutide therapy led to a gradual recovery of metabolic complications allowing tapering-down other medications. Conclusions Considering the pleiotropic effects of GLP1-a beyond BMI reduction, this treatment modality may serve as a game changer in challenging cases.
AbstractList AimImplementing genetic analyses have unraveled rare alterations causing early-onset obesity and complications, in whom treatment is challenging. We aimed to report on the effects of adjuvant off-label therapy with liraglutide, glucagon-like peptide-1 analogue (GLP-1a), in rare genetic diagnoses.MethodsCase scenarios and review of the literature.ResultsCase 1: Nine-year-old boy with early-onset severe obesity and nonalcoholic fatty liver disease (NAFLD) due to a homozygous mutation in the MC4R gene deteriorated under lifestyle change and metformin therapy [at 10.5 years: body mass index (BMI) 51.2kg/m2, 226% of the 95th percentile, fat percentage (FP) 65% and muscle-to-fat ratio (MFR) z-score of −2.41]. One year of liraglutide treatment halted progressive weight gain [BMI 50.3kg/m2, 212% of the 95th percentile, 63.7% FP and MFR z-score of −2.34], with biochemical improvement.Case 2: Twelve-year-old boy with obesity presented with diabetes and progressive NAFLD. Exome analysis revealed two heterozygous mutations compatible with monogenic diabetes (HNF1A) and familial hypercholesterolemia (LDLR). Lifestyle modifications resulted in clinical and laboratory improvement (BMI 87th percentile, 32.8% FP, MFR z-score of −1.63, HbA1c 5.5%) without the expected recovery in liver transaminases. Liraglutide treatment augmented the improvement in weight status (BMI 68th percentile, 22.6% FP, MFR z-score of −1.13) with normalization of liver transaminases.Case 3: Nineteen-year-old male with spinal muscular atrophy type 3 presented with sarcopenic obesity and comorbidities. Treatment strategy included dietary counseling and multiple drug therapies (metformin, anti-hypertensive and statins). Liraglutide therapy led to a gradual recovery of metabolic complications allowing tapering-down other medications.ConclusionsConsidering the pleiotropic effects of GLP1-a beyond BMI reduction, this treatment modality may serve as a game changer in challenging cases.
Aim Implementing genetic analyses have unraveled rare alterations causing early-onset obesity and complications, in whom treatment is challenging. We aimed to report on the effects of adjuvant off-label therapy with liraglutide, glucagon-like peptide-1 analogue (GLP-1a), in rare genetic diagnoses. Methods Case scenarios and review of the literature. Results Case 1: Nine-year-old boy with early-onset severe obesity and nonalcoholic fatty liver disease (NAFLD) due to a homozygous mutation in the MC4R gene deteriorated under lifestyle change and metformin therapy [at 10.5 years: body mass index (BMI) 51.2kg/m 2 , 226% of the 95th percentile, fat percentage (FP) 65% and muscle-to-fat ratio (MFR) z-score of −2.41]. One year of liraglutide treatment halted progressive weight gain [BMI 50.3kg/m 2 , 212% of the 95th percentile, 63.7% FP and MFR z-score of −2.34], with biochemical improvement. Case 2: Twelve-year-old boy with obesity presented with diabetes and progressive NAFLD. Exome analysis revealed two heterozygous mutations compatible with monogenic diabetes ( HNF1A ) and familial hypercholesterolemia ( LDLR ). Lifestyle modifications resulted in clinical and laboratory improvement (BMI 87th percentile, 32.8% FP, MFR z-score of −1.63, HbA1c 5.5%) without the expected recovery in liver transaminases. Liraglutide treatment augmented the improvement in weight status (BMI 68th percentile, 22.6% FP, MFR z-score of −1.13) with normalization of liver transaminases. Case 3: Nineteen-year-old male with spinal muscular atrophy type 3 presented with sarcopenic obesity and comorbidities. Treatment strategy included dietary counseling and multiple drug therapies (metformin, anti-hypertensive and statins). Liraglutide therapy led to a gradual recovery of metabolic complications allowing tapering-down other medications. Conclusions Considering the pleiotropic effects of GLP1-a beyond BMI reduction, this treatment modality may serve as a game changer in challenging cases.
Implementing genetic analyses have unraveled rare alterations causing early-onset obesity and complications, in whom treatment is challenging. We aimed to report on the effects of adjuvant off-label therapy with liraglutide, glucagon-like peptide-1 analogue (GLP-1a), in rare genetic diagnoses. Case scenarios and review of the literature. Case 1: Nine-year-old boy with early-onset severe obesity and nonalcoholic fatty liver disease (NAFLD) due to a homozygous mutation in the MC4R gene deteriorated under lifestyle change and metformin therapy [at 10.5 years: body mass index (BMI) 51.2kg/m , 226% of the 95th percentile, fat percentage (FP) 65% and muscle-to-fat ratio (MFR) z-score of -2.41]. One year of liraglutide treatment halted progressive weight gain [BMI 50.3kg/m , 212% of the 95th percentile, 63.7% FP and MFR z-score of -2.34], with biochemical improvement. Case 2: Twelve-year-old boy with obesity presented with diabetes and progressive NAFLD. Exome analysis revealed two heterozygous mutations compatible with monogenic diabetes (HNF1A) and familial hypercholesterolemia (LDLR). Lifestyle modifications resulted in clinical and laboratory improvement (BMI 87th percentile, 32.8% FP, MFR z-score of -1.63, HbA1c 5.5%) without the expected recovery in liver transaminases. Liraglutide treatment augmented the improvement in weight status (BMI 68th percentile, 22.6% FP, MFR z-score of -1.13) with normalization of liver transaminases. Case 3: Nineteen-year-old male with spinal muscular atrophy type 3 presented with sarcopenic obesity and comorbidities. Treatment strategy included dietary counseling and multiple drug therapies (metformin, anti-hypertensive and statins). Liraglutide therapy led to a gradual recovery of metabolic complications allowing tapering-down other medications. Considering the pleiotropic effects of GLP1-a beyond BMI reduction, this treatment modality may serve as a game changer in challenging cases.
AIMImplementing genetic analyses have unraveled rare alterations causing early-onset obesity and complications, in whom treatment is challenging. We aimed to report on the effects of adjuvant off-label therapy with liraglutide, glucagon-like peptide-1 analogue (GLP-1a), in rare genetic diagnoses. METHODSCase scenarios and review of the literature. RESULTSCase 1: Nine-year-old boy with early-onset severe obesity and nonalcoholic fatty liver disease (NAFLD) due to a homozygous mutation in the MC4R gene deteriorated under lifestyle change and metformin therapy [at 10.5 years: body mass index (BMI) 51.2kg/m2, 226% of the 95th percentile, fat percentage (FP) 65% and muscle-to-fat ratio (MFR) z-score of -2.41]. One year of liraglutide treatment halted progressive weight gain [BMI 50.3kg/m2, 212% of the 95th percentile, 63.7% FP and MFR z-score of -2.34], with biochemical improvement. Case 2: Twelve-year-old boy with obesity presented with diabetes and progressive NAFLD. Exome analysis revealed two heterozygous mutations compatible with monogenic diabetes (HNF1A) and familial hypercholesterolemia (LDLR). Lifestyle modifications resulted in clinical and laboratory improvement (BMI 87th percentile, 32.8% FP, MFR z-score of -1.63, HbA1c 5.5%) without the expected recovery in liver transaminases. Liraglutide treatment augmented the improvement in weight status (BMI 68th percentile, 22.6% FP, MFR z-score of -1.13) with normalization of liver transaminases. Case 3: Nineteen-year-old male with spinal muscular atrophy type 3 presented with sarcopenic obesity and comorbidities. Treatment strategy included dietary counseling and multiple drug therapies (metformin, anti-hypertensive and statins). Liraglutide therapy led to a gradual recovery of metabolic complications allowing tapering-down other medications. CONCLUSIONSConsidering the pleiotropic effects of GLP1-a beyond BMI reduction, this treatment modality may serve as a game changer in challenging cases.
Author Chorna, Efrat
Lubetzky, Ronit
Moran-Lev, Hadar
Lebenthal, Yael
Zaitoon, Hussein
Sagi, Liora
Yacobi-Bach, Michal
Amir, Achiya Z.
Brener, Avivit
Borger, Ophir
Author_xml – sequence: 1
  givenname: Hussein
  surname: Zaitoon
  fullname: Zaitoon, Hussein
  organization: Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children’s Hospital, Tel Aviv Sourasky Medical Center
– sequence: 2
  givenname: Ronit
  surname: Lubetzky
  fullname: Lubetzky, Ronit
  organization: Sackler Faculty of Medicine, Tel Aviv University, Department of Pediatrics, Dana-Dwek Children’s Hospital, Tel Aviv Sourasky Medical Center
– sequence: 3
  givenname: Achiya Z.
  surname: Amir
  fullname: Amir, Achiya Z.
  organization: Sackler Faculty of Medicine, Tel Aviv University, Pediatric Gastroenterology Institute, Dana-Dwek Children’s Hospital, Tel Aviv Sourasky Medical Center
– sequence: 4
  givenname: Hadar
  surname: Moran-Lev
  fullname: Moran-Lev, Hadar
  organization: Sackler Faculty of Medicine, Tel Aviv University, Pediatric Gastroenterology Institute, Dana-Dwek Children’s Hospital, Tel Aviv Sourasky Medical Center
– sequence: 5
  givenname: Liora
  surname: Sagi
  fullname: Sagi, Liora
  organization: Sackler Faculty of Medicine, Tel Aviv University, Pediatric Neurology Institute, Dana-Dwek Children’s Hospital, Tel Aviv Sourasky Medical Center
– sequence: 6
  givenname: Michal
  surname: Yacobi-Bach
  fullname: Yacobi-Bach, Michal
  organization: The Genetics Institute, Tel Aviv Sourasky Medical Center, Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center
– sequence: 7
  givenname: Ophir
  surname: Borger
  fullname: Borger, Ophir
  organization: Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children’s Hospital, Tel Aviv Sourasky Medical Center, The Nutrition and Dietetics Unit, Tel Aviv Sourasky Medical Center
– sequence: 8
  givenname: Efrat
  surname: Chorna
  fullname: Chorna, Efrat
  organization: Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children’s Hospital, Tel Aviv Sourasky Medical Center, Social Services, Tel Aviv Sourasky Medical Center
– sequence: 9
  givenname: Yael
  surname: Lebenthal
  fullname: Lebenthal, Yael
  organization: Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children’s Hospital, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University
– sequence: 10
  givenname: Avivit
  orcidid: 0000-0002-2742-8264
  surname: Brener
  fullname: Brener, Avivit
  email: avivitb@tlvmc.gov.il
  organization: Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children’s Hospital, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37160786$$D View this record in MEDLINE/PubMed
BookMark eNp9kU9P3DAQxS0EKrDtF-BQWeqFA6H-s4nj3irUQiUkLvRs2c5kMU3s4EkOe-4Xx3RpQRx6GNl6_s2bkd8x2Y8pAiEnnJ1zxtRnZKzWomJCluJMV3qPHPG1FFUtpNx_dT8kx4j3jHGhZPuOHErFG6ba5oj8vhwWbzcpVkP4BXSCaQ4dVJzaaIe0ofMdZDttaYg02wx0AxHm4GkXECwCfqFjiqmoRUsOMMzbs1dSF6yDGfCs-HUUp1Bc6bigXwabqZ1zmu6278lBbweED8_nivz8_u324qq6vrn8cfH1uvJS1XPV-oZDWdopAR5c18NaCeekqAVrVeu57d1aC29ZX0QpOHfrRrVC8KYrBXJFTne-U04PC-BsxoAehsFGSAsa0XKupZZMFfTTG_Q-Lbks_0QJzVpdl29fEbGjfE6IGXoz5TDavDWcmaeIzC4iU1jzJyKjS9PHZ-vFjdD9a_mbSQHkDsDyFDeQX2b_x_YRIV6enw
CitedBy_id crossref_primary_10_1159_000537921
crossref_primary_10_1016_j_bcp_2024_116133
Cites_doi 10.1542/peds.2008-1349
10.1016/J.NMD.2020.02.011
10.1016/J.MOLMET.2019.09.010
10.1016/J.NEUINT.2019.04.010
10.1515/CCLM.2010.315/MACHINEREADABLECITATION/RIS
10.4093/DMJ.2019.0018
10.1016/J.TEM.2019.09.003
10.1038/S41576-021-00414-Z
10.1016/J.PEPTIDES.2019.170183
10.1016/J.HJC.2018.11.008
10.1016/J.XCRM.2020.100006
10.7150/IJBS.59965
10.1093/CVR/CVW216
10.1056/NEJMOA1916038
10.1007/BF00280883
10.1016/S2468-1253(19)30383-8
10.3389/FENDO.2020.00178
10.1056/NEJMOA2028395
10.1111/ACEL.13202
10.1016/B978-0-12-820683-6.00022-1
10.1038/S41422-022-00692-0
10.1111/DOM.13162
10.1016/j.vaccine.2010.09.034
10.1016/J.MCE.2021.111472
10.1016/J.GENDIS.2021.06.010
10.1016/J.EPRAC.2020.10.013
10.1016/J.BBAMCR.2022.119300
10.2174/1573399819666220610150342
10.1016/J.METABOL.2019.154044
10.1016/J.JPEDS.2021.05.009
10.2337/DC13-3007
10.1016/J.METABOL.2019.04.014
10.1542/9781581109405-genetic
10.3389/FENDO.2021.721135
10.1038/AJG.2016.517
10.3389/FENDO.2022.852290
10.1111/J.2047-6310.2013.00168.X
10.1016/S2213-8587(22)00047-X
10.1038/S41366-019-0357-5
10.3390/METABO12050430
10.3390/METABO11020073
ContentType Journal Article
Copyright Springer-Verlag Italia S.r.l., part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2023. Springer-Verlag Italia S.r.l., part of Springer Nature.
Copyright_xml – notice: Springer-Verlag Italia S.r.l., part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2023. Springer-Verlag Italia S.r.l., part of Springer Nature.
DBID NPM
AAYXX
CITATION
7T5
H94
K9.
7X8
DOI 10.1007/s00592-023-02109-9
DatabaseName PubMed
CrossRef
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList AIDS and Cancer Research Abstracts

PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1432-5233
EndPage 1108
ExternalDocumentID 10_1007_s00592_023_02109_9
37160786
Genre Journal Article
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
199
1N0
2.D
203
23M
28-
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3V.
4.4
406
408
409
40D
40E
53G
5QI
5VS
67Z
6NX
78A
7X7
88E
8AO
8FI
8FJ
8G5
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AABYN
AAFGU
AAHNG
AAIAL
AAJKR
AAKSU
AANXM
AANZL
AAPBV
AARHV
AARTL
AATNV
AATVU
AAUYE
AAWCG
AAYFA
AAYIU
AAYQN
AAYTO
ABBBX
ABBXA
ABDZT
ABECU
ABFGW
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKAS
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABPTK
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACBMV
ACBRV
ACBXY
ACBYP
ACGFS
ACHSB
ACHXU
ACIGE
ACIPQ
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPRK
ACSNA
ACTTH
ACUDM
ACVWB
ACWMK
ADBBV
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADMDM
ADOXG
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEEQQ
AEFIE
AEFTE
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AENEX
AEOHA
AEPYU
AESKC
AESTI
AETLH
AEVLU
AEVTX
AEXYK
AFAFS
AFEXP
AFKRA
AFLOW
AFNRJ
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGBP
AGGDS
AGJBK
AGKHE
AGMZJ
AGQMX
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHMBA
AHSBF
AHYZX
AIAKS
AIIXL
AILAN
AIMYW
AITGF
AJBLW
AJDOV
AJRNO
AJZVZ
AKMHD
AKQUC
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DWQXO
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNUQQ
GNWQR
GQ6
GQ7
GQ8
GRRUI
GUQSH
GXS
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KOV
KOW
KPH
LAS
LLZTM
M1P
M2O
M4Y
MA-
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R89
R9I
RHV
RIG
RNI
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UNUBA
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
YLTOR
Z45
Z7U
Z7W
Z82
Z87
Z8O
Z8Q
Z8V
Z91
ZA5
ZMTXR
ZOVNA
~A9
~EX
AACDK
AAEOY
AAJBT
AASML
AAYZH
ABAKF
ACAOD
ACDTI
ACZOJ
AEFQL
AEMSY
AFBBN
AGQEE
AGRTI
AIGIU
AJOOF
ALIPV
H13
NPM
AAYXX
CITATION
7T5
H94
K9.
7X8
ID FETCH-LOGICAL-c375t-8c61e786b72ecebdfe472bb32520878c1afb492ca0fb323211b46782216d216e3
IEDL.DBID AGYKE
ISSN 1432-5233
0940-5429
IngestDate Fri Oct 25 01:16:47 EDT 2024
Wed Nov 06 08:30:41 EST 2024
Fri Nov 22 01:14:21 EST 2024
Wed Oct 16 00:38:49 EDT 2024
Sat Dec 16 12:03:28 EST 2023
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords Early-onset severe obesity
Childhood obesity
MC4R gene mutation
Hepatic nuclear factor 1 alpha (HNF1α MODY)
Spinal muscular atrophy (SMA) type 3
Language English
License 2023. Springer-Verlag Italia S.r.l., part of Springer Nature.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c375t-8c61e786b72ecebdfe472bb32520878c1afb492ca0fb323211b46782216d216e3
Notes ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Review-3
content type line 23
ObjectType-Feature-5
ObjectType-Article-4
ObjectType-Report-1
ORCID 0000-0002-2742-8264
PMID 37160786
PQID 2829089502
PQPubID 49275
PageCount 10
ParticipantIDs proquest_miscellaneous_2811939307
proquest_journals_2829089502
crossref_primary_10_1007_s00592_023_02109_9
pubmed_primary_37160786
springer_journals_10_1007_s00592_023_02109_9
PublicationCentury 2000
PublicationDate 2023-08-01
PublicationDateYYYYMMDD 2023-08-01
PublicationDate_xml – month: 08
  year: 2023
  text: 2023-08-01
  day: 01
PublicationDecade 2020
PublicationPlace Milan
PublicationPlace_xml – name: Milan
– name: Germany
– name: Heidelberg
PublicationTitle Acta diabetologica
PublicationTitleAbbrev Acta Diabetol
PublicationTitleAlternate Acta Diabetol
PublicationYear 2023
Publisher Springer Milan
Springer Nature B.V
Publisher_xml – name: Springer Milan
– name: Springer Nature B.V
References Hira, Pinyo, Hara (CR17) 2020; 31
Iepsen, Have, Veedfald (CR37) 2020
Abdulla, Phillips, Wilkinson (CR43) 2020; 19
Gasbjerg, Bergmann, Stensen (CR12) 2020
Basalay, Mastitskaya, Mrochek (CR15) 2016; 112
Kelly, Auerbach, Barrientos-Perez (CR21) 2020; 382
Newsome, Sasso, Deeks (CR29) 2020; 5
Newsome, Buchholtz, Cusi (CR34) 2021; 384
Ayan, DeMirci (CR45) 2022
Liu, Zhu, Jiang (CR6) 2022; 9
Holst (CR11) 2019; 96
Jebeile, Kelly, O’Malley, Baur (CR1) 2022; 10
Zhao, Wang, Wen (CR19) 2021
Ceriotti, Henny, Queraltó (CR35) 2010; 48
Farooqi (CR5) 2021; 181
CR33
CR32
CR30
Brener, Lebenthal, Shtamler (CR7) 2020; 30
Wu, Zhou, Li (CR41) 2022
McCarthy, Samani-Radia, Jebb, Prentice (CR25) 2014; 9
Matthews, Hosker, Rudenski (CR26) 1985; 287
Daniels, Greer (CR27) 2008
Nur ZatiIwani, Jalaludin, Yahya (CR28) 2022
Andrikou, Tsioufis, Andrikou (CR14) 2019; 60
Grinbaum, Beglaibter, Mitrani-Rosenbaum (CR31) 2022; 12
Mantovani, Petracca, Beatrice (CR40) 2021; 11
Ma, Liu, Ilyas (CR13) 2021; 17
Gilbert, Pratley (CR18) 2020
Spencer, Hibberd (CR10) 2022
Talbot, Brown, Kirkland (CR16) 2010; 28
Østoft, Bagger, Hansen (CR39) 2014; 37
Serra-Juhé, Martos-Moreno, Bou de Pieri (CR2) 2020; 44
Aroda (CR20) 2018; 20
Kwo, Cohen, Lim (CR36) 2017; 112
CR23
Bae, Choi, Cho (CR38) 2020; 44
Loos, Yeo (CR3) 2022; 23
Ryan, Seltzer, Hayward (CR22) 2021; 236
Smith, Hackett, Galli, Flynn (CR8) 2019; 128
Brener, Peleg, Rosenfeld (CR24) 2021; 27
Gurjar, Kushwaha, Chattopadhyay (CR44) 2020; 103
Müller, Finan, Bloom (CR9) 2019; 30
Thaker (CR4) 2017; 28
Yamada, Ogura, Inoue (CR42) 2022; 539
E Ayan (2109_CR45) 2022
2109_CR23
AK Nur ZatiIwani (2109_CR28) 2022
R Grinbaum (2109_CR31) 2022; 12
PY Kwo (2109_CR36) 2017; 112
NK Smith (2109_CR8) 2019; 128
H Abdulla (2109_CR43) 2020; 19
X Ma (2109_CR13) 2021; 17
IS Farooqi (2109_CR5) 2021; 181
VR Aroda (2109_CR20) 2018; 20
VV Thaker (2109_CR4) 2017; 28
X Zhao (2109_CR19) 2021
PM Ryan (2109_CR22) 2021; 236
TD Müller (2109_CR9) 2019; 30
LS Gasbjerg (2109_CR12) 2020
F Ceriotti (2109_CR35) 2010; 48
SH Østoft (2109_CR39) 2014; 37
AS Kelly (2109_CR21) 2020; 382
MV Basalay (2109_CR15) 2016; 112
JH Bae (2109_CR38) 2020; 44
EA Talbot (2109_CR16) 2010; 28
DR Matthews (2109_CR26) 1985; 287
AA Gurjar (2109_CR44) 2020; 103
HD McCarthy (2109_CR25) 2014; 9
MP Gilbert (2109_CR18) 2020
2109_CR30
E Andrikou (2109_CR14) 2019; 60
2109_CR32
F Liu (2109_CR6) 2022; 9
2109_CR33
EW Iepsen (2109_CR37) 2020
S Yamada (2109_CR42) 2022; 539
H Jebeile (2109_CR1) 2022; 10
RJF Loos (2109_CR3) 2022; 23
JJ Holst (2109_CR11) 2019; 96
PN Newsome (2109_CR29) 2020; 5
L Wu (2109_CR41) 2022
T Hira (2109_CR17) 2020; 31
A Brener (2109_CR24) 2021; 27
A Brener (2109_CR7) 2020; 30
NJ Spencer (2109_CR10) 2022
C Serra-Juhé (2109_CR2) 2020; 44
SR Daniels (2109_CR27) 2008
PN Newsome (2109_CR34) 2021; 384
A Mantovani (2109_CR40) 2021; 11
References_xml – year: 2008
  ident: CR27
  article-title: Lipid screening and cardiovascular health in childhood
  publication-title: Pediatrics
  doi: 10.1542/peds.2008-1349
  contributor:
    fullname: Greer
– volume: 30
  start-page: 270
  year: 2020
  end-page: 276
  ident: CR7
  article-title: The endocrine manifestations of spinal muscular atrophy, a real-life observational study
  publication-title: Neuromuscul Disord
  doi: 10.1016/J.NMD.2020.02.011
  contributor:
    fullname: Shtamler
– volume: 30
  start-page: 72
  year: 2019
  end-page: 130
  ident: CR9
  article-title: Glucagon-like peptide 1 (GLP-1)
  publication-title: Mol Metab
  doi: 10.1016/J.MOLMET.2019.09.010
  contributor:
    fullname: Bloom
– volume: 128
  start-page: 94
  year: 2019
  ident: CR8
  article-title: GLP-1: molecular mechanisms and outcomes of a complex signaling system
  publication-title: Neurochem Int
  doi: 10.1016/J.NEUINT.2019.04.010
  contributor:
    fullname: Flynn
– ident: CR30
– volume: 48
  start-page: 1593
  year: 2010
  end-page: 1601
  ident: CR35
  article-title: Common reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT) in serum: results from an IFCC multicenter study
  publication-title: Clin Chem Lab Med
  doi: 10.1515/CCLM.2010.315/MACHINEREADABLECITATION/RIS
  contributor:
    fullname: Queraltó
– volume: 44
  start-page: 248
  year: 2020
  ident: CR38
  article-title: Glucagon-like peptide-1 receptor agonist differentially affects brain activation in response to visual food cues in lean and obese individuals with type 2 diabetes mellitus
  publication-title: Diabetes Metab J
  doi: 10.4093/DMJ.2019.0018
  contributor:
    fullname: Cho
– volume: 31
  start-page: 71
  year: 2020
  end-page: 80
  ident: CR17
  article-title: What Is GLP-1 really doing in obesity?
  publication-title: Trends Endocrinol Metab
  doi: 10.1016/J.TEM.2019.09.003
  contributor:
    fullname: Hara
– volume: 23
  start-page: 120
  year: 2022
  end-page: 133
  ident: CR3
  article-title: The genetics of obesity: from discovery to biology
  publication-title: Nat Rev Genet
  doi: 10.1038/S41576-021-00414-Z
  contributor:
    fullname: Yeo
– year: 2020
  ident: CR12
  article-title: Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
  publication-title: Peptides
  doi: 10.1016/J.PEPTIDES.2019.170183
  contributor:
    fullname: Stensen
– volume: 60
  start-page: 347
  year: 2019
  end-page: 351
  ident: CR14
  article-title: GLP-1 receptor agonists and cardiovascular outcome trials: an update
  publication-title: Hellenic J Cardiol
  doi: 10.1016/J.HJC.2018.11.008
  contributor:
    fullname: Andrikou
– ident: CR33
– year: 2020
  ident: CR37
  article-title: GLP-1 receptor agonist treatment in morbid obesity and type 2 diabetes due to pathogenic homozygous melanocortin-4 receptor mutation: a case report
  publication-title: Cell reports Med
  doi: 10.1016/J.XCRM.2020.100006
  contributor:
    fullname: Veedfald
– volume: 17
  start-page: 2050
  year: 2021
  end-page: 2068
  ident: CR13
  article-title: GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
  publication-title: Int J Biol Sci
  doi: 10.7150/IJBS.59965
  contributor:
    fullname: Ilyas
– volume: 112
  start-page: 669
  year: 2016
  end-page: 676
  ident: CR15
  article-title: Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning
  publication-title: Cardiovasc Res
  doi: 10.1093/CVR/CVW216
  contributor:
    fullname: Mrochek
– volume: 382
  start-page: 2117
  year: 2020
  end-page: 2128
  ident: CR21
  article-title: A randomized, controlled trial of liraglutide for adolescents with obesity
  publication-title: N Engl J Med
  doi: 10.1056/NEJMOA1916038
  contributor:
    fullname: Barrientos-Perez
– volume: 287
  start-page: 412
  issue: 28
  year: 1985
  end-page: 419
  ident: CR26
  article-title: (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
  publication-title: Diabetol
  doi: 10.1007/BF00280883
  contributor:
    fullname: Rudenski
– volume: 5
  start-page: 362
  year: 2020
  end-page: 373
  ident: CR29
  article-title: FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
  publication-title: Lancet Gastroenterol Hepatol
  doi: 10.1016/S2468-1253(19)30383-8
  contributor:
    fullname: Deeks
– year: 2020
  ident: CR18
  article-title: GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/FENDO.2020.00178
  contributor:
    fullname: Pratley
– volume: 384
  start-page: 1113
  year: 2021
  end-page: 1124
  ident: CR34
  article-title: A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMOA2028395
  contributor:
    fullname: Cusi
– ident: CR23
– volume: 19
  start-page: e13202
  year: 2020
  ident: CR43
  article-title: Glucagon-like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle
  publication-title: Aging Cell
  doi: 10.1111/ACEL.13202
  contributor:
    fullname: Wilkinson
– volume: 181
  start-page: 301
  year: 2021
  end-page: 310
  ident: CR5
  article-title: Monogenic human obesity syndromes
  publication-title: Handb Clin Neurol
  doi: 10.1016/B978-0-12-820683-6.00022-1
  contributor:
    fullname: Farooqi
– year: 2022
  ident: CR10
  article-title: GLP-1 appetite control via intestinofugal neurons
  publication-title: Cell Res
  doi: 10.1038/S41422-022-00692-0
  contributor:
    fullname: Hibberd
– volume: 20
  start-page: 22
  issue: Suppl 1
  year: 2018
  end-page: 33
  ident: CR20
  article-title: A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials
  publication-title: Diabetes Obes Metab
  doi: 10.1111/DOM.13162
  contributor:
    fullname: Aroda
– volume: 28
  start-page: 8001
  year: 2010
  end-page: 8007
  ident: CR16
  article-title: The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2010.09.034
  contributor:
    fullname: Kirkland
– volume: 539
  start-page: 111472
  year: 2022
  ident: CR42
  article-title: Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats
  publication-title: Mol Cell Endocrinol
  doi: 10.1016/J.MCE.2021.111472
  contributor:
    fullname: Inoue
– volume: 9
  start-page: 1248
  year: 2022
  ident: CR6
  article-title: Transcriptional control by HNF-1: emerging evidence showing its role in lipid metabolism and lipid metabolism disorders
  publication-title: Genes Dis
  doi: 10.1016/J.GENDIS.2021.06.010
  contributor:
    fullname: Jiang
– volume: 27
  start-page: 419
  year: 2021
  end-page: 425
  ident: CR24
  article-title: Beyond body mass index - body composition assessment by bioimpedance in routine endocrine practice
  publication-title: Endocr Pract
  doi: 10.1016/J.EPRAC.2020.10.013
  contributor:
    fullname: Rosenfeld
– year: 2022
  ident: CR41
  article-title: GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway
  publication-title: Biochim Biophys acta Mol cell Res
  doi: 10.1016/J.BBAMCR.2022.119300
  contributor:
    fullname: Li
– year: 2022
  ident: CR45
  article-title: A brief atlas of insulin
  publication-title: Curr Diabetes Rev
  doi: 10.2174/1573399819666220610150342
  contributor:
    fullname: DeMirci
– volume: 103
  start-page: 154044
  year: 2020
  ident: CR44
  article-title: Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents
  publication-title: Metabolism
  doi: 10.1016/J.METABOL.2019.154044
  contributor:
    fullname: Chattopadhyay
– volume: 236
  start-page: 137
  year: 2021
  end-page: 147.e13
  ident: CR22
  article-title: Safety and efficacy of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity: a meta-analysis
  publication-title: J Pediatr
  doi: 10.1016/J.JPEDS.2021.05.009
  contributor:
    fullname: Hayward
– volume: 37
  start-page: 1797
  year: 2014
  end-page: 1805
  ident: CR39
  article-title: Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial
  publication-title: Diabetes Care
  doi: 10.2337/DC13-3007
  contributor:
    fullname: Hansen
– volume: 96
  start-page: 46
  year: 2019
  end-page: 55
  ident: CR11
  article-title: The incretin system in healthy humans: the role of GIP and GLP-1
  publication-title: Metabolism
  doi: 10.1016/J.METABOL.2019.04.014
  contributor:
    fullname: Holst
– ident: CR32
– volume: 28
  start-page: 379
  year: 2017
  end-page: 405
  ident: CR4
  article-title: Genetic and epigenetic causes of obesity
  publication-title: Adolesc Med State Art Rev
  doi: 10.1542/9781581109405-genetic
  contributor:
    fullname: Thaker
– year: 2021
  ident: CR19
  article-title: GLP-1 receptor agonists: beyond their pancreatic effects
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/FENDO.2021.721135
  contributor:
    fullname: Wen
– volume: 112
  start-page: 18
  year: 2017
  end-page: 35
  ident: CR36
  article-title: ACG clinical guideline: evaluation of abnormal liver chemistries
  publication-title: Am J Gastroenterol
  doi: 10.1038/AJG.2016.517
  contributor:
    fullname: Lim
– year: 2022
  ident: CR28
  article-title: TG: HDL-C ratio as insulin resistance marker for metabolic syndrome in children with obesity
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/FENDO.2022.852290
  contributor:
    fullname: Yahya
– volume: 9
  start-page: 249
  year: 2014
  end-page: 259
  ident: CR25
  article-title: Skeletal muscle mass reference curves for children and adolescents
  publication-title: Pediatr Obes
  doi: 10.1111/J.2047-6310.2013.00168.X
  contributor:
    fullname: Prentice
– volume: 10
  start-page: 351
  year: 2022
  end-page: 365
  ident: CR1
  article-title: Obesity in children and adolescents: epidemiology, causes, assessment, and management
  publication-title: Lancet Diabetes Endocrinol
  doi: 10.1016/S2213-8587(22)00047-X
  contributor:
    fullname: Baur
– volume: 44
  start-page: 830
  year: 2020
  end-page: 841
  ident: CR2
  article-title: Heterozygous rare genetic variants in non-syndromic early-onset obesity
  publication-title: Int J Obes (Lond)
  doi: 10.1038/S41366-019-0357-5
  contributor:
    fullname: Bou de Pieri
– volume: 12
  start-page: 430
  year: 2022
  ident: CR31
  article-title: The Obesogenic and glycemic effect of bariatric surgery in a family with a melanocortin 4 receptor loss-of-function mutation
  publication-title: Metabolites
  doi: 10.3390/METABO12050430
  contributor:
    fullname: Mitrani-Rosenbaum
– volume: 11
  start-page: 1
  year: 2021
  end-page: 13
  ident: CR40
  article-title: Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials
  publication-title: Metabolites
  doi: 10.3390/METABO11020073
  contributor:
    fullname: Beatrice
– volume: 236
  start-page: 137
  year: 2021
  ident: 2109_CR22
  publication-title: J Pediatr
  doi: 10.1016/J.JPEDS.2021.05.009
  contributor:
    fullname: PM Ryan
– volume: 5
  start-page: 362
  year: 2020
  ident: 2109_CR29
  publication-title: Lancet Gastroenterol Hepatol
  doi: 10.1016/S2468-1253(19)30383-8
  contributor:
    fullname: PN Newsome
– volume: 44
  start-page: 830
  year: 2020
  ident: 2109_CR2
  publication-title: Int J Obes (Lond)
  doi: 10.1038/S41366-019-0357-5
  contributor:
    fullname: C Serra-Juhé
– year: 2021
  ident: 2109_CR19
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/FENDO.2021.721135
  contributor:
    fullname: X Zhao
– volume: 27
  start-page: 419
  year: 2021
  ident: 2109_CR24
  publication-title: Endocr Pract
  doi: 10.1016/J.EPRAC.2020.10.013
  contributor:
    fullname: A Brener
– volume: 10
  start-page: 351
  year: 2022
  ident: 2109_CR1
  publication-title: Lancet Diabetes Endocrinol
  doi: 10.1016/S2213-8587(22)00047-X
  contributor:
    fullname: H Jebeile
– year: 2008
  ident: 2109_CR27
  publication-title: Pediatrics
  doi: 10.1542/peds.2008-1349
  contributor:
    fullname: SR Daniels
– volume: 181
  start-page: 301
  year: 2021
  ident: 2109_CR5
  publication-title: Handb Clin Neurol
  doi: 10.1016/B978-0-12-820683-6.00022-1
  contributor:
    fullname: IS Farooqi
– volume: 23
  start-page: 120
  year: 2022
  ident: 2109_CR3
  publication-title: Nat Rev Genet
  doi: 10.1038/S41576-021-00414-Z
  contributor:
    fullname: RJF Loos
– volume: 19
  start-page: e13202
  year: 2020
  ident: 2109_CR43
  publication-title: Aging Cell
  doi: 10.1111/ACEL.13202
  contributor:
    fullname: H Abdulla
– year: 2022
  ident: 2109_CR10
  publication-title: Cell Res
  doi: 10.1038/S41422-022-00692-0
  contributor:
    fullname: NJ Spencer
– volume: 37
  start-page: 1797
  year: 2014
  ident: 2109_CR39
  publication-title: Diabetes Care
  doi: 10.2337/DC13-3007
  contributor:
    fullname: SH Østoft
– volume: 30
  start-page: 72
  year: 2019
  ident: 2109_CR9
  publication-title: Mol Metab
  doi: 10.1016/J.MOLMET.2019.09.010
  contributor:
    fullname: TD Müller
– ident: 2109_CR30
– year: 2022
  ident: 2109_CR45
  publication-title: Curr Diabetes Rev
  doi: 10.2174/1573399819666220610150342
  contributor:
    fullname: E Ayan
– volume: 28
  start-page: 379
  year: 2017
  ident: 2109_CR4
  publication-title: Adolesc Med State Art Rev
  doi: 10.1542/9781581109405-genetic
  contributor:
    fullname: VV Thaker
– ident: 2109_CR32
– volume: 28
  start-page: 8001
  year: 2010
  ident: 2109_CR16
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2010.09.034
  contributor:
    fullname: EA Talbot
– ident: 2109_CR23
– volume: 9
  start-page: 1248
  year: 2022
  ident: 2109_CR6
  publication-title: Genes Dis
  doi: 10.1016/J.GENDIS.2021.06.010
  contributor:
    fullname: F Liu
– volume: 112
  start-page: 18
  year: 2017
  ident: 2109_CR36
  publication-title: Am J Gastroenterol
  doi: 10.1038/AJG.2016.517
  contributor:
    fullname: PY Kwo
– volume: 287
  start-page: 412
  issue: 28
  year: 1985
  ident: 2109_CR26
  publication-title: Diabetol
  doi: 10.1007/BF00280883
  contributor:
    fullname: DR Matthews
– year: 2022
  ident: 2109_CR28
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/FENDO.2022.852290
  contributor:
    fullname: AK Nur ZatiIwani
– volume: 30
  start-page: 270
  year: 2020
  ident: 2109_CR7
  publication-title: Neuromuscul Disord
  doi: 10.1016/J.NMD.2020.02.011
  contributor:
    fullname: A Brener
– year: 2020
  ident: 2109_CR18
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/FENDO.2020.00178
  contributor:
    fullname: MP Gilbert
– volume: 60
  start-page: 347
  year: 2019
  ident: 2109_CR14
  publication-title: Hellenic J Cardiol
  doi: 10.1016/J.HJC.2018.11.008
  contributor:
    fullname: E Andrikou
– volume: 112
  start-page: 669
  year: 2016
  ident: 2109_CR15
  publication-title: Cardiovasc Res
  doi: 10.1093/CVR/CVW216
  contributor:
    fullname: MV Basalay
– year: 2020
  ident: 2109_CR12
  publication-title: Peptides
  doi: 10.1016/J.PEPTIDES.2019.170183
  contributor:
    fullname: LS Gasbjerg
– ident: 2109_CR33
– volume: 128
  start-page: 94
  year: 2019
  ident: 2109_CR8
  publication-title: Neurochem Int
  doi: 10.1016/J.NEUINT.2019.04.010
  contributor:
    fullname: NK Smith
– volume: 31
  start-page: 71
  year: 2020
  ident: 2109_CR17
  publication-title: Trends Endocrinol Metab
  doi: 10.1016/J.TEM.2019.09.003
  contributor:
    fullname: T Hira
– volume: 48
  start-page: 1593
  year: 2010
  ident: 2109_CR35
  publication-title: Clin Chem Lab Med
  doi: 10.1515/CCLM.2010.315/MACHINEREADABLECITATION/RIS
  contributor:
    fullname: F Ceriotti
– volume: 20
  start-page: 22
  issue: Suppl 1
  year: 2018
  ident: 2109_CR20
  publication-title: Diabetes Obes Metab
  doi: 10.1111/DOM.13162
  contributor:
    fullname: VR Aroda
– volume: 11
  start-page: 1
  year: 2021
  ident: 2109_CR40
  publication-title: Metabolites
  doi: 10.3390/METABO11020073
  contributor:
    fullname: A Mantovani
– volume: 17
  start-page: 2050
  year: 2021
  ident: 2109_CR13
  publication-title: Int J Biol Sci
  doi: 10.7150/IJBS.59965
  contributor:
    fullname: X Ma
– volume: 384
  start-page: 1113
  year: 2021
  ident: 2109_CR34
  publication-title: N Engl J Med
  doi: 10.1056/NEJMOA2028395
  contributor:
    fullname: PN Newsome
– volume: 539
  start-page: 111472
  year: 2022
  ident: 2109_CR42
  publication-title: Mol Cell Endocrinol
  doi: 10.1016/J.MCE.2021.111472
  contributor:
    fullname: S Yamada
– year: 2020
  ident: 2109_CR37
  publication-title: Cell reports Med
  doi: 10.1016/J.XCRM.2020.100006
  contributor:
    fullname: EW Iepsen
– volume: 44
  start-page: 248
  year: 2020
  ident: 2109_CR38
  publication-title: Diabetes Metab J
  doi: 10.4093/DMJ.2019.0018
  contributor:
    fullname: JH Bae
– year: 2022
  ident: 2109_CR41
  publication-title: Biochim Biophys acta Mol cell Res
  doi: 10.1016/J.BBAMCR.2022.119300
  contributor:
    fullname: L Wu
– volume: 9
  start-page: 249
  year: 2014
  ident: 2109_CR25
  publication-title: Pediatr Obes
  doi: 10.1111/J.2047-6310.2013.00168.X
  contributor:
    fullname: HD McCarthy
– volume: 12
  start-page: 430
  year: 2022
  ident: 2109_CR31
  publication-title: Metabolites
  doi: 10.3390/METABO12050430
  contributor:
    fullname: R Grinbaum
– volume: 103
  start-page: 154044
  year: 2020
  ident: 2109_CR44
  publication-title: Metabolism
  doi: 10.1016/J.METABOL.2019.154044
  contributor:
    fullname: AA Gurjar
– volume: 96
  start-page: 46
  year: 2019
  ident: 2109_CR11
  publication-title: Metabolism
  doi: 10.1016/J.METABOL.2019.04.014
  contributor:
    fullname: JJ Holst
– volume: 382
  start-page: 2117
  year: 2020
  ident: 2109_CR21
  publication-title: N Engl J Med
  doi: 10.1056/NEJMOA1916038
  contributor:
    fullname: AS Kelly
SSID ssj0012738
Score 2.4034932
SecondaryResourceType review_article
Snippet Aim Implementing genetic analyses have unraveled rare alterations causing early-onset obesity and complications, in whom treatment is challenging. We aimed to...
Implementing genetic analyses have unraveled rare alterations causing early-onset obesity and complications, in whom treatment is challenging. We aimed to...
AimImplementing genetic analyses have unraveled rare alterations causing early-onset obesity and complications, in whom treatment is challenging. We aimed to...
AIMImplementing genetic analyses have unraveled rare alterations causing early-onset obesity and complications, in whom treatment is challenging. We aimed to...
SourceID proquest
crossref
pubmed
springer
SourceType Aggregation Database
Index Database
Publisher
StartPage 1099
SubjectTerms Age
Antihypertensives
Body mass index
Body weight gain
Comorbidity
Diabetes
Diabetes mellitus
Fatty liver
Genetic analysis
Genetic disorders
Glucagon
Glucagon-like peptide 1
Hypercholesterolemia
Internal Medicine
Literature reviews
Liver diseases
Medicine
Medicine & Public Health
Metabolic Diseases
Metformin
Mutation
Neuromuscular diseases
Obesity
Original Article
Peptides
Spinal muscular atrophy
Statins
Title Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy
URI https://link.springer.com/article/10.1007/s00592-023-02109-9
https://www.ncbi.nlm.nih.gov/pubmed/37160786
https://www.proquest.com/docview/2829089502
https://search.proquest.com/docview/2811939307
Volume 60
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9swDCbWBhh2WbtX57YLNGC3RYUl23r0lg5Ngg3tqQG6k2HJ8lB0tYMmOXTX_fFSfnVDtkMOvtCybIuUSIn8SIBPCdcqtFbSArUrjfOM0cxEluJmQhuWGRNbf95xcSlm8_jrdXL9hOOug907j2S9UPdYNw-T5BRVDPXbFE31DgxQ9_jZOBhPv387750HHm3S4mP-_eTfOmjDsNxwita6ZrIHVx1ipwkxuT1Zr8yJ_bWZwHGb39iHl63tScaNsLyCZ658Dc8vWu_6G_g99SXQflQl_Xlz68jCB7zkjjKSlf6IhzRYrQdyUxLcYjuCsuchkKR18ixPCcp0hVSkVU3BgdEfpO6Yd4T95WS58PW4yN26iYQl_kweWf4W5pPzqy8z2hZpoDaSyYoqK5iTShjJnXUmL1wsuTERT3iopLIsK0ysuc3CAokRMszg2oxmCRM5Xi56B7tlVbr3QEQeulgZkTFpYqYs9iLwSWlcLnRShAF87tiWLppcHGmfdbke1xTHNa3HNdUBHHecTdt5uUxrv7HSScgD-Njfxhnl3SRZ6aq1b8PQqtW4-AVw0EhE_7pI-oR8SgQw6tj71Pn_v-Vwu-ZH8ILXEuLjDI9hd3W_dh_Q9lmZIcr65OzsctjK_BB25nz8CG23_ek
link.rule.ids 314,780,784,27924,27925,41081,41523,42150,42592,52111,52234
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LTtwwcNQuUsul9AVNocWVemONYifxgxuqgOWxnFgJTlHsOAgByaq7eyhXfrzjvKClPXDIZWI7jmfseY8Bvidcq9BaSQvkrjTOM0YzE1mKyoQ2LDMmtt7eMT4Vo0l8dJ6ct0lhsy7avXNJ1id1n-zm8yQ5RR5DvZ6iqX4JSzFyrHAAS7sHF8d7vffAp5u0CTL_7vknE3oiWT7xitbMZn8FJt00mxiT6-3F3Gzbu78qOD73P97Cm1b6JLsNubyDF658D6_GrX_9A9wf-EvQLquS3lxdOzL1IS-5o4xkpTfykCZb6xe5Kgkq2Y4g9fkkSNK6eWY7BKm6QijCqubKgeEjUGfoHeJ4OZlN_Y1c5HbRxMISb5VHpH-Eyf7e2Y8Rba9poDaSyZwqK5iTShjJnXUmL1wsuTERT3iopLIsK0ysuc3CAoERapwGT2cUTJjI8XHRKgzKqnSfgIg8dLEyImPSxExZHEVgT2lcLnRShAFsdXhLp001jrSvu1yva4rrmtbrmuoANjrUpu3OnKW151jpJOQBfOtf457yjpKsdNXCt2Eo12o8_gJYa0ii_1wkfUk-JQIYduh9GPz_c_n8vOab8Hp0Nj5JTw5Pj9dhmdfU4qMON2Aw_7lwX1ASmpuvLeH_Bm7Z_1g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9wwEB61VEK9oNJneNWVeutaxE7iR2-osKUPUA9diVsUOw5ChWTF7h4488c7k1epKIcecpnYTpRvnBnPE-B9Jq2Jvde8QunK07IQvHCJ53iYsE4UzqWe7B0np-p4ln49y87uZPG30e6DS7LLaaAqTfVyf15W-2PiG-VMSo7yhtOZxXL7GJ6QKCJOn8mD0Y9AiSd9qsy_5_0tju7pmPf8o63YmT6DjV5fZAcdwJvwKNTPYf2k94i_gNvP1LbsvKn55cWvwOYUpFIGLlhRk1mGdflVN-yiZngsDgz5hdIWWe-YWXxkyIcNUpHWdE0CJndIg2l2guuVbDGnHlrsatVFrzKyoyNML2E2Pfr56Zj3jRW4T3S25MYrEbRRTsvggyurkGrpXCIzGRttvCgql1rpi7hCYoJnRIf_U1QlhCrxCskrWKubOrwBpso4pMapQmiXCuNxFYUztQulslkVR_Bh-L75vKufkY-Vkls0ckQjb9HIbQQ7AwR5v5cWeevrNTaLZQTvxtu4C8i1UdShWdEYgZqoxR9WBK876MbHJZqK6BkVwWTA8s_iD7_L1v8NfwvrPw6n-fcvp9-24alsWYzCBHdgbXm9CruouizdXsudvwFPrear
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Glucagon-like+peptide-1+analog+therapy+in+rare+genetic+diseases%3A+monogenic+obesity%2C+monogenic+diabetes%2C+and+spinal+muscular+atrophy&rft.jtitle=Acta+diabetologica&rft.au=Zaitoon%2C+Hussein&rft.au=Lubetzky%2C+Ronit&rft.au=Amir%2C+Achiya+Z&rft.au=Moran-Lev%2C+Hadar&rft.date=2023-08-01&rft.eissn=1432-5233&rft.volume=60&rft.issue=8&rft.spage=1099&rft_id=info:doi/10.1007%2Fs00592-023-02109-9&rft_id=info%3Apmid%2F37160786&rft.externalDocID=37160786
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1432-5233&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1432-5233&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1432-5233&client=summon